04/09/2025
7:00 AM | Goodman Noah (Reporting)
Kymera Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
04/09/2025
7:05 AM | Goodman Noah (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/01/2025
7:00 AM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:30 PM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:30 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:30 PM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:30 PM | Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:30 PM | Chiniara Ellen (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/03/2025
5:00 PM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/03/2025
5:00 PM | Chiniara Ellen (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/03/2025
5:00 PM | Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
03/03/2025
5:00 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/03/2025
3:30 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/27/2025
6:33 AM | Kymera Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/27/2025
6:13 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/27/2025
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/10/2025
9:25 AM | Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
| Form SCHEDULE 13G/A | |
01/14/2025
3:02 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/13/2025
6:00 AM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
6:00 AM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/02/2024
6:50 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/02/2024
3:41 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2024
8:30 AM | Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
9:52 AM | Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
| Form SC 13G/A | |
10/31/2024
7:13 AM | Kymera Therapeutics (Filer)
| Form S-3ASR | |
10/31/2024
6:40 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
6:45 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
09/17/2024
5:20 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/17/2024
3:40 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
5:31 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/26/2024
3:32 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
3:25 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2024
4:06 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
3:15 PM | BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13D/A | |
08/22/2024
3:03 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
4:24 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/20/2024
3:31 PM | Kymera Therapeutics (Filer)
| Form 424B5 | |
08/07/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2024
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/25/2024
5:12 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024
4:17 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
$2 Trillion Disappears Because of Fed's Secretive New Move (Ad) $2 trillion has disappeared from the US government's books.
The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth. Click here to see his new research now. |
07/16/2024
5:00 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:28 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/15/2024
3:31 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024
4:15 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/09/2024
3:16 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024
3:18 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024
4:05 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
7:30 AM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
Morgan Leigh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
MARAGANORE JOHN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Hrustanovic Gorjan (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
Ridloff Elena (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:01 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2024
7:30 AM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
5:01 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
4:14 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/13/2024
4:15 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024
4:23 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024
4:24 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
5:36 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:27 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/23/2024
4:22 PM | Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/02/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
Buy KYMR Stock Free KYMR Stock Alerts